AU2000227285A1 - Methods of regulating il-12 production by administering ccr5 agonists and antagonists - Google Patents

Methods of regulating il-12 production by administering ccr5 agonists and antagonists

Info

Publication number
AU2000227285A1
AU2000227285A1 AU2000227285A AU2728500A AU2000227285A1 AU 2000227285 A1 AU2000227285 A1 AU 2000227285A1 AU 2000227285 A AU2000227285 A AU 2000227285A AU 2728500 A AU2728500 A AU 2728500A AU 2000227285 A1 AU2000227285 A1 AU 2000227285A1
Authority
AU
Australia
Prior art keywords
antagonists
administering
regulating
production
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2000227285A
Inventor
Julio Cesar Soares Aliberti
Alan Sher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
US Government
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, US Government filed Critical US Department of Health and Human Services
Publication of AU2000227285A1 publication Critical patent/AU2000227285A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2000227285A 2000-01-14 2000-01-14 Methods of regulating il-12 production by administering ccr5 agonists and antagonists Abandoned AU2000227285A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/001019 WO2001051077A1 (en) 2000-01-14 2000-01-14 Methods of regulating il-12 production by administering ccr5 agonists and antagonists

Publications (1)

Publication Number Publication Date
AU2000227285A1 true AU2000227285A1 (en) 2001-07-24

Family

ID=21740972

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2000227285A Abandoned AU2000227285A1 (en) 2000-01-14 2000-01-14 Methods of regulating il-12 production by administering ccr5 agonists and antagonists

Country Status (2)

Country Link
AU (1) AU2000227285A1 (en)
WO (1) WO2001051077A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2472682A1 (en) * 2002-01-22 2003-07-31 Merck & Co., Inc. Treating stress response with chemokine receptor ccr5 modulators
KR100615389B1 (en) * 2002-08-23 2006-08-25 (주)헬릭서 Health food comprising the extract of Actinidia arguta and related species for the prevention and improvement of allergic disease and non-allergic inflammatory disease
AT412145B (en) * 2002-09-13 2004-10-25 Forsch Krebskranke Kinder METHOD FOR PRODUCING A CELLULAR IMMUNOTHERAPEUTICUM BASED ON IL-12 RELEASING DENDRITIC CELLS
CA2548502A1 (en) 2003-12-11 2005-06-30 Yale University Methods and compositions relating to ccr5 antagonist, ifn-.gamma. and il-13 induced inflammation
WO2006128172A2 (en) * 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating b cell regulated autoimmune disorders
PE20081785A1 (en) 2007-02-19 2009-01-12 Novartis Ag CYCLOHEXYL-AMIDE DERIVATIVES OF ARYL CARBOXYL ACID
CN113040090A (en) * 2021-04-13 2021-06-29 南京医科大学 Method for constructing animal model of autism and corresponding application

Also Published As

Publication number Publication date
WO2001051077A1 (en) 2001-07-19

Similar Documents

Publication Publication Date Title
AU2003209259A1 (en) Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
EP1536828A4 (en) Methods of delivery of exogenous proteins to the cytosol and uses thereof
AU2002316230A1 (en) Methods of culturing animal cells and polypeptide production in animal cells
AU5763900A (en) Methods of enriching for and identifying polymorphisms
AU2002232819A1 (en) Methods for the production of multimeric proteins, and related compositions
AU2003277215A1 (en) Novel neurokinin antagonists and methods of use thereof
AU2000227285A1 (en) Methods of regulating il-12 production by administering ccr5 agonists and antagonists
AU2003294762A1 (en) Film-type preparations for transmucosal administration of nicotine and method for the production thereof
AU2002341555A1 (en) Levothyroxine pharmaceutical compositions, methods of making and methods of administration
MY127675A (en) Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
AU2003252138A1 (en) Cementitious composition comprising bottom ash, methods of making and use thereof
AU2002339673A1 (en) Agonists and antagonists of ryzn for the treatment of metabolic disorders
WO2003044169A3 (en) Compositions and methods for reversibly inducing continual growth in normal cells
AU2002328173A1 (en) Omoxin agonists and antagonists for use in the treatment of metabolic disorders
IL160160A0 (en) SUBSTITUTED 5,6,6a, 11b-TETRAHYDRO-7-OXA-5-AZA-BENZO[c]FLUORENE-6-CARBOXYLIC ACID DERIVATIVES SERVING AS NMDA ANTAGONISTS
AU3489700A (en) Oral compositions and methods of production thereof
AU2002339680A1 (en) Agonists and antagonists of bromix for the treatment of metabolic disorders
AU2002324297A1 (en) Agonists and antagonists of moxifin for the treatment of metabolic disorders
AU2002339685A1 (en) Agonists and antagonists of oxifan for the treatment of metabolic disorders
AU2002339681A1 (en) Agonists and antagonists of glucomin for the treatment of metabolic disorders
AU2002329001A1 (en) Agonists and antagonists of cylixin for the treatment of metabolic disorders
AU2002321770A1 (en) Agonists and antagonists of genceptin for the treatment of metabolic disorders
AU2002313580A1 (en) Xobesin agonists and antagonists for the treatment of metabolic disorders
AU2002321761A1 (en) Agonists and antagonists of disomet for the treatment of metabolic disorders
AU2002321766A1 (en) Agonists and antagonists of obesingen for the treatment of metabolic disorders